← Full evidence page

For the cleanest result, disable browser headers and footers.

Dediabetes Evidence Brief

Cardiometabolic Risk in Diabetes: Blood Pressure, Cholesterol, and Heart Outcomes

Evidence related to blood pressure, lipid profile, cardiovascular risk, cardiovascular events, and cardiometabolic risk markers in diabetes.

Brief accessed
—

Full evidence pagehttps://www.dediabetes.com/evidence/cardiometabolic-risk

Executive Summary

Cardiometabolic Risk evidence appears to center on Metformin.

Among 9 indexed studies and 4 interventions, the strongest signals are summarized from the available evidence. Resistance training has been studied often, while Metformin appears to have stronger current evidence signals.

  • No strong consistent positive evidence pattern was detected.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Evidence Snapshot

Studies analyzed
9
Evidence relationships
17
Interventions
4
Outcomes
8
Strong evidence signals
0
Mixed evidence areas
1

Key Findings

  1. 01

    Across 2 studies, SGLT2 inhibitors shows a moderate positive signal for All-cause mortality.

  2. 02

    Across 1 study, Exercise therapy shows a neutral signal for HDL cholesterol.

  3. 03

    Across 1 study, Exercise therapy shows a neutral signal for LDL cholesterol.

  4. 04

    Across 1 study, Exercise therapy shows a neutral signal for lipid profiles.

Question Highlights

Does SGLT2 inhibitors improve all-cause mortality?

SGLT2 inhibitors may improve All-cause mortality.

Moderate evidence is based on 2 supporting studies.

Some evidence reported benefits while other evidence found little or no effect.

Read the full answer

Evidence Categories

The evidence is organized by how consistently it supports a conclusion and how much research is available.

Well-Supported Interventions

The strongest and most consistent evidence for improving this outcome.

No strong consistent positive evidence pattern was detected.

Interpretation

The current evidence does not yet show a clear consistent-benefit pattern.

Findings Requiring Careful Interpretation

Results that vary across studies or depend on population, study design, duration, or comparator.

Some evidence is positive, but results are not consistent across all studies.

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Resistance training is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Leading examples

Resistance training · SGLT2 inhibitors · Exercise therapy

Evidence basis: 17 evidence pairs - 9 studies

Emerging Areas of Research

Early positive signals that require additional high-quality research.

Early findings are encouraging, but stronger trials are needed.

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

SGLT2 inhibitors may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Leading examples

SGLT2 inhibitors · Metformin

Evidence basis: 9 evidence pairs - 5 studies

About this Evidence Brief

This brief summarizes research currently indexed by Dediabetes Evidence Intelligence. It is not a clinical guideline or personalized medical recommendation. Evidence classifications may change as additional studies are indexed.

Suggested citation

—